Search

Your search keyword '"Hilden, Joanne M."' showing total 331 results

Search Constraints

Start Over You searched for: Author "Hilden, Joanne M." Remove constraint Author: "Hilden, Joanne M."
331 results on '"Hilden, Joanne M."'

Search Results

1. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG

2. Early career mentoring through the American Society of Pediatric Hematology/Oncology: Lessons learned from a pilot program

3. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

6. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia

7. KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children’s Oncology Group P9407 trial study

8. Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

11. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Childrenʼs Oncology Group study AALL1131

13. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia

14. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study

15. Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial

18. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the childrenʼs oncology group

19. Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)

21. Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children’s Oncology Group AALL1131.

28. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Childrenʼs Oncology Group trial A2971: A report from the Childrenʼs Oncology Group

33. CONTRIBUTORS

36. Brain Tumors

37. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children’s Oncology Group Study AALL1131

41. FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

49. Tell the Children

Catalog

Books, media, physical & digital resources